Bris­tol My­ers pass­es on two Ex­sci­en­tia on­col­o­gy can­di­dates, but biotech to move them in­to clin­ic next year

Ex­sci­en­tia said it ex­pand­ed its pipeline Tues­day morn­ing, but the biotech is do­ing so with­out the help of a years­long part­ner: Bris­tol My­ers Squibb.

The Big Phar­ma has de­cid­ed not to move for­ward with two on­col­o­gy de­vel­op­ment can­di­dates, Ex­sci­en­tia said. The AI-dri­ven UK biotech plans to start test­ing the com­pounds in the clin­ic next year on its own, CEO An­drew Hop­kins told End­points News.

“We took this as part of a rou­tine port­fo­lio pri­or­i­ti­za­tion hap­pen­ing in BMS and oth­er Big Phar­ma at the mo­ment,” Hop­kins said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER